For Healthcare Professionals

Observational Study of Adult Participants With Diabetic Macular Edema and Suboptimal Response to Anti-Vascular Endothelial Growth Factor Treated With Dexamethasone Intravitreal Implant

clipboard-pencil

About the study

The dexamethasone 700 μg intravitreal implant (DEX-I) delivers dexamethasone gradually to the retina over time. It is an approved drug for the treatment of DME. This study will assess adult participants with diabetic macular edema (DME) and suboptimal response to anti-vascular endothelial growth factor therapy that are treated with DEX-I in the routine clinical setting. Approximately 327 participants who are prescribed DEX-I by their physicians will be enrolled at approximately 40 sites in approximately 10 countries globally. Participants will be followed for 18 months post-DEX-I implantation according to the routine clinical practice of the prescribing centers. Only one eye per participant will be evaluated in the study. No additional burden for participants in this trial is expected.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Participant diagnosed with DME in the study eye
  2. Study eye has received at least 3 and no more than 9 anti-VEGF injections in the 12 months prior to DEX-I initiation
  3. Study eye newly prescribed DEX-I. The prescribing decision lies with the physician and reflects their standard practice
  4. Participant showing a suboptimal response to anti-VEGF at Baseline in the study eye

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Any concomitant ocular or neurologic condition in the study eye that could cause macular edema or affect vision (except cataract)
  2. History of ocular surgery within 60 days of Baseline in the study eye
  3. History of Pan-Retinal Photocoagulation (PRP) or sectorial photocoagulation in the study eye in the 3 months prior to Baseline
  4. Significant media opacities in the study eye limiting Optical Coherence Tomography (OCT) quality
  5. Uncontrolled Ocular Hypertension (OHT) or advanced glaucoma in the study eye
  6. Active ocular inflammation in either eye
  7. Study eyes that are aphakic with Posterior Capsule Rent (PCR), Anterior Chamber Intraocular Lens (ACIOL), iris or scleral-fixed Intraocular Lens (IOL) or history of complicated cataract surgery with PCR
  8. Prior use of intravitreal corticosteroids in the study eye
  9. Patients with contraindications to DEX-I
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 844-663-3742Email iconEmail Study Center

Study Details


Contition

Diabetic Macular Edema

Age

18+

Participants Needed

327

Est. Completion Date

Jun 13, 2026

Treatment Type

OBSERVATIONAL


Sponsor

AbbVie

ClinicalTrials.gov NCT Identifier

NCT05978622

Study Number

P23-380

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.